Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/05—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/32—Burseraceae (Frankincense family)
  • A61K36/324—Boswellia, e.g. frankincense
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/906—Zingiberaceae (Ginger family)
  • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• the present invention relates generally to dietary supplement compositions, and more particularly to a composition comprising resveratrol and turmeric extract.
• the claimed dietary supplement possesses anti-inflammatory, analgesic, cartilage protectant and antioxidant properties.
• Inflammation and various inflammatory disorders are highly prevalent, afflicting large percentages of the world's population. Inflammation is a necessary response of the body to counteract the threat of infectious agents and other foreign bodies, and is characterized by symptoms such as pain, redness, heat, swelling and decreased function. These symptoms are caused by a variety of inflammatory mediators acting in concert, such as prostaglandins, thromboxane, and leukotrienes. Overexpression of these factors is implicated in a variety of conditions, particularly rheumatoid arthritis, an autoimmune disease characterized by chronic inflammation and cartilage destruction.
• the present invention is directed to a dietary supplement composition
• a dietary supplement composition comprising resveratrol and turmeric extract.
• the claimed dietary supplement is useful as a nutritional supplement, anti-inflammatory, analgesic, cartilage protectant and/or antioxidant.
• the present invention further provides a method for treating, ameliorating or preventing inflammation, pain, cartilage deterioration or oxidative degradation through the administration of a dietary supplement composition comprising resveratrol and turmeric extract.
• the present invention provides a dietary supplement composition
• a dietary supplement composition comprising resveratrol and turmeric extract.
• the claimed dietary supplement is useful as a nutritional supplement, anti-inflammatory, analgesic, cartilage protectant and/or antioxidant.
• the present invention further provides a method for treating, ameliorating or preventing inflammation, pain, cartilage deterioration or oxidative degradation through the administration of a dietary supplement composition comprising resveratrol and turmeric extract.
• the claimed dietary supplement composition further comprises stinging nettle and/or Boswellia serrata.
• the resveratrol and turmeric extract inhibit the enzymes cyclooxygenase and 5- lipoxygenase and/orthe production of their products, prostaglandins (PG), leukotrienes (LT), and thromboxanes (TX). Through such inhibition, they exhibit anti-inflammatory and analgesic effects.
• the body's production of other molecules mediating the production of these enzyme products is also blocked, such as interleukins (IL) and tumor necrosis factor (TNF).
• IL interleukins
• TNF tumor necrosis factor
• Turmeric further acts as an antioxidant, complementing these anti-inflammatory and analgesic effects.
• Both Boswellia serrata and turmeric further exert cartilage protectant properties, thereby acting in the areas of the joints, a prime site for pain and/or inflammation to arise.
• the claimed composition comprises about 1 to about 4000 mg of resveratrol and about 1 mg to about 4000 mg of turmeric extract.
• the claimed composition comprises from about 10 mg to about 400 mg of resveratrol and about 50 mg to about 450 mg of turmeric extract. Still more preferably, such composition comprises from about 15 mg to about 45 mg of resveratrol.
• the claimed composition comprises about 30 mg of resveratrol, and about 50 mg of turmeric extract.
• the claimed composition comprises about 1 to about 4000 mg of resveratrol, about 1 mg to about 4000 mg of turmeric extract, about 1 mg to about 4000 mg of stinging nettle and about 1 mg to about 4000 mg of Boswellia serrata.
• such composition comprises about 10 to about 400 mg of resveratrol (more preferably about 15 to about 45 mg), about 50 mg to about 450 mg of turmeric extract, about 50 mg to about 400 mg of stinging nettle and about 100 mg to about 400 mg of Boswellia serrata.
• such composition comprises about 30 mg of resveratrol, about 50 mg of turmeric extract, about 50 mg of stinging nettle and about 200 mg of Boswellia serrata.
• composition claimed herein utilizes stinging nettles as a component.
• the type of this component employed in the practice of the invention is one that is standardized to "1% of silicic acid". This means that an extract of stinging nettles concentrated to contain 1% of silicic acid is preferably used.
• Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a ubiquitous phytoalexin synthesized by numerous plant species. Since relatively high quantities are found in grape skin (Vitis vinifera) and red wines, resveratrol is routinely incorporated into the average diet. Resveratrol has been proposed to alter the production of eicosanoids, a family of molecules involved in inflammation, pain perception and immune response, including prostaglandins (PGs), fhromboxanes (TXs) and leukotrienes (LTs).
• PGs prostaglandins
• TXs fhromboxanes
• LTs leukotrienes
• the arachidonic acid pathway is responsible for the production of eicosanoids.
• Arachidonic acid is the starting compound for two different pathways, one mediated by cyclooxygenase enzymes (i.e. COX-2) and one by lipoxygenase enzymes (i.e. 5- LOX).
• the arachidonic acid pathway is also mediated by a group of molecules called cytol nes, which include interleukins (ILs) and tumor necrosis factor (TNF- ⁇ ).
• ILs interleukins
• TNF- ⁇ tumor necrosis factor
• Resveratrol is a potent inhibitor of both the cyclooxygenase (COX) and lipoxygenase (LOX) pathways.
• COX-1 and COX-2 are key enzymes that catalyze the biosynthesis of eicosanoids such as prostaglandins.
• Non-steroidal anti-inflammatory drugs act by inhibiting both COX-1 and COX-2. Inhibition of COX-1 is the basis for the adverse side effects associated with prolonged use of NSAIDs.
• Resveratrol inhibits COX-2 only, and therefore does not cause these side effects, but retains the anti-inflammatory and analgesic actions.. Studies have shown that resveratrol not only inhibits the COX-2 enzyme directly, but also completely blocks its synthesis as represented by decreased levels of COX-2 protein, mRNA and gene promoter activity.
• the involved region of the COX-2 promoter has been determined.
• Resveratrol also completely inhibited signaling molecules protein kinase C, c-Jun, ERK1 and AP-1, effectively blocking the signal transduction pathway necessary for the induction of the COX-2 geneProduction of many of the major eicosanoids is thereby inhibited, including COX-2 products PGE 2 (prostaglandin E2), PGF 2 (prostaglandin F2), PGD 2 (prostaglandin D2), TXB 2 (thromboxane B2) and HHT (12-hydroxy-5,8,10-heptadecatrienoic acid), and 5-LOX products 5-HETE (5-hydroxy-6,8,l 1,14-eicosatetraenoic acid-), 5,12-diHETE (5, 12- hydroxy-6,8,11,14-eicosatetraenoic acid)and LTC 4 (leukotriene C4).
• PGE 2 prostaglandin E2
• PGF 2 prostag
• resveratrol also has an effect on cytokines. Incubation of mouse macrophages with resveratrol inhibited the production of the IL- 6 by 34%.
• resveratrol An additional effect of resveratrol is its ability to inhibit the induction of inducible nitric oxide synthase (iNOS).
• iNOS mediates the synthesis of nitric oxide, which modulates a range of physiological responses including inflammation.
• Leukotrienes, products of the LOX pathway, are involved in immunoregulation and in a variety of diseases, including asthma, inflammation and various allergic conditions.
• 5-hydroperoxy-6,8,l 1,14-eicosatetraenoic acid 5-HPETE
• 5-hydroxy-6,8,l 1,14-eicosatetraenoic acid 5-HETE
• LTA4 the unstable intermediate leukotriene A4
• Resveratrol strongly inhibits the formation of 5-HETE.
• 5-HETE was inhibited by greater than 70%.
• LOX products 5,12-diHETE, 5-HETE and LTC4 were also inhibited.
• Resveratrol also stimulates cAMP levels, dose dependently. It is well accepted that cAMP plays an important role in inflammatory events. It is thought that cAMP is involved in the control of a variety of inflammatory and immunologic processes, such as the release of histamine, leukotrienes and lysosomal enzymes.
• Resveratrol is commercially available. For example, it is sold by InterHealth Nutraceuticals, Inc. of Benicia, CA, under the tradename Protykin®.
• turmeric (Curcuma longa) has been reported to possess anti- inflammatory, anticarcinogenic and free radical scavenging properties in animals.
• the active component isolated from turmeric is curcumin (diferuloyl methane), which is responsible for its color and flavor.
• curcumin directly blocks the activity of COX-2 and 5- LOX in rat and human cell lines. Curcumin also inhibits the synthesis of new COX-2 protein and mRNA. It has further been demonstrated that products of these pathways are also reduced, including PGE2, LTB4 and LTC4.
• the cytokines IL-1B, IL-8 and TNF- ⁇ were also inhibited by at least 50% in human cell lines.
• the mechanism by which curcumin affects these molecules is recently coming to light.
• the cytokines TNF-a and IL-1B activate NF-KB, a transcription factor that turns on multiple genes involved in inflammation.
• Studies have shown that curcumin blocks factors that remove the inhibitory molecule I-KBa from the NF-KB molecule, effectively keeping NF-KB in a dormant stage. As a result, genes encoding pro- inflammatory molecules are not turned on. It has been shown that production of IL-8 is blocked in this way.
• turmeric The potency of turmeric has been evaluated in comparison to other anti- inflammatory drugs.
• the anti- inflammatory actions of curcumin were compared to phenylbutazone in patients with rheumatoid arthritis.
• Curcumin provided significant improvement in the duration of morning stiffness, walking time and joint swelling compared to phenylbutazone.
• curcumin has a lower ulcerogen index (0.6) than a similar active dose of phenylbutazone (1.7) based on an animal study.
• tumeric component useful in the practice of the present invention is commercially available.
• a preferred standardized form of the tumeric component namely turmeric extract (95% curcuminoids)
• turmeric extract 95% curcuminoids
• Curcumin C Complex is commercially available from Sabinsa Corporation of Piscataway, NJ under the tradename Curcumin C Complex.
• Stinging Nettle (Urtica dioica L.) is named for the fine silica-rich hairs that cover its stem and leaves and break off when touched. Nettle has been used for centuries as an herbal remedy for a variety of conditions. It has been shown that stinging nettle extracts inhibit the expression of several cytokines as well as eicosanoid formation in blood cells. Cytokines, in particular tumor necrosis factor (TNF), are elevated in the synovial fluid in arthritic conditions and are presumably involved in the disease process by up-regulating multiple inflammatory mediators.
• TNF tumor necrosis factor
• NF- ⁇ B transcription factor NF- ⁇ B
• NF- ⁇ B transcription factor NF- ⁇ B
• IL-1 pro-inflammatory molecules
• IL-2 pro-inflammatory molecules
• IL-6 pro-inflammatory molecules
• IL-8 pro-inflammatory molecules
• TNF- ⁇ B activation is increased, leading to the over- expression of pro-inflammatory gene products.
• NF- ⁇ B is ubiquitously found as an inactive complex in the cytoplasm bound to its inhibitory sub-unit I ⁇ B.
• the extract of stinging nettle is known to markedly inhibit production of NF- ⁇ B in human cell lines. Research suggests that the extracts stabilizes the inhibitor I ⁇ B- ⁇ by preventing its proteolytic degradation. Stinging nettle also directly inhibits the production of TNF- ⁇ and IL-1 ⁇ .
• AP-1 activator protein- 1
• AP-1 activation may be responsible for synovial hyperplasia in rheumatoid arthritis.
• Target genes of AP-1 include matrix metalloproteinases, which are involved in degrading connective tissues. AP-1 can physically interact with NF- ⁇ B and cooperatively induce cytokine gene expression. It has been demonstrated that leaf extract from stinging nettle potently inhibited AP- 1.
• Stinging nettle is commercially available.
• t e preferred standardized form of the component namely stinging nettle (1% silicic acid), is sold by Pharmachem Laboratories, Inc. of Kearny, NJ, under the tradename PE Stinging Nettle 1%.
• Boswellia serrata 65% boswellic acid
• frankincense pentacyclic triterpenes called boswellic acids (BAs).
• BAs have been shown to affect the activity of 5-lipoxygenase and leukocytes, both significantly involved in the inflammatory response.
• In vitro studies in human leukocytes and rat neutrophils have demonstrated that BAs specifically inhibit the synthesis of products of 5-lipoxygenase (LTB4, LTC4, 5,12-diHETE and 5-HETE) by greater than 80%. This effect is due to the binding of BAs to 5-lipoxygenase in a way that prevents the binding of its natural substrate, arachidonate.
• BAs dramatically decreased the migration and total count of leukocytes to arthritic. BAs have also been shown to have a positive effect on arthritic symptoms.
• BAs prevented inflammation and arthritic activity in developing and established arthritis. Anti-inflammatory agents often decrease the content and synthesis of glycosaminoglycans, important components of cartilage degraded in arthritis. BAs reduce the synthesis, but not the total content of glycosaminoglycans, suggesting that BAs inhibit the destruction of cartilage.
• Pentacyclic triterpenes from sources other than Boswellia inhibit 5-lipoxygenase but do not additionally inhibit cartilage- destructive enzymes. BAs are well tolerated. In acute, sub-acute and chronic toxicity studies with mice, rats and monkeys, no adverse effects or deaths were recorded. Even at doses of 1000 mg/kg, BAs had no ulcerogenic effects, as does aspirin.
• Boswellia serrata component useful in the practice of the current inveniton is commercially available.
• the preferred standardized form of the Boswellia serrata namely Boswellia serrata (65% boswellic acid)
• Boswellin® is commercially available from Sabinsa Corporation under the tradename Boswellin®.
• the claimed composition may be administered in the form of pharmaceutically acceptable tablets, capsules, powder, paste, solutions, suspension or gel dosage forms.
• tablets or capsules are used.
• the route of administration is via the alimentary tract.
• the claimed composition may be administered whenever inflammation or pain (acute or chronic) is experienced.
• the composition may further be taken to prevent or ameliorate inflammation, pain, cartilage deterioration or oxidative degradation.
• composition appears to be non-toxic, there is no known upper limit on the intake of the claimed composition. Because the components of the claimed composition are biologically derived, the dosages thereof will further vary with the concentration of the individual components therein. Additional modifications and improvements of the present invention may also by apparent to those skilled in the art. Thus, the particular combination of parts described and illustrated herein is intended to represent only one embodiment of the invention, and is not intended to serve as limitations of alternative devices within the spirit and scope of the invention.

Landscapes

• Health & Medical Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicines Containing Plant Substances (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=22786319

Family Applications (1)

Country Status (8)

Families Citing this family (8)

Citations (4)

Family Cites Families (3)

• 2001
  • 2001-06-13 CA CA002412435A patent/CA2412435A1/fr not_active Abandoned
  • 2001-06-13 IL IL15332001A patent/IL153320A0/xx unknown
  • 2001-06-13 WO PCT/US2001/018989 patent/WO2001095727A1/fr not_active Ceased
  • 2001-06-13 AU AU2001266895A patent/AU2001266895A1/en not_active Abandoned
  • 2001-06-13 MX MXPA02012340A patent/MXPA02012340A/es not_active Application Discontinuation
  • 2001-06-13 HK HK03106579.3A patent/HK1054296A1/zh unknown
  • 2001-06-13 EP EP01944487A patent/EP1289369A4/fr not_active Withdrawn
• 2002
  • 2002-12-08 IL IL153320A patent/IL153320A/en active IP Right Grant
  • 2002-12-10 ZA ZA200209986A patent/ZA200209986B/en unknown

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events